Partial Heart Transplantation for Severe Pediatric Semilunar Valve Dysfunction

NCT05372757 | Completed

• 1 other identifier: 00114653
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

The long-term goal of this research initiative is to develop a new valve replacement option for neonates, infants and young children. The central hypothesis is that transplantation of a freshly isolated heart valve will be associated with superior outcomes compared to currently available options, including preserved cadaver valves, bioprosthetic tissue valves, or mechanical valves. This new operation has been named "partial heart transplantation". The proposed study is a single-center, nonrandomized single arm pilot trial of "partial heart transplantation" in neonates, infants and young children who require semilunar heart valve replacement. This "first in man" trial seeks to determine whether valve replacement using partial heart transplant is feasible and safe. Primary aims are survival one year and five years following the procedure. The hypothesis is that, when compared to historical controls who have undergone homograft valve replacement, those undergoing partial heart transplantation will have equal or superior survival one year and five years following the procedure. Secondary aims are to assess growth and function of the transplanted valve. The hypothesis is that when compared to historical controls who have undergone conventional valve replacement, those undergoing partial heart transplantation will have valve growth that corresponds with somatic growth and superior valve function 1 year following the procedure. Up to five patients will be enrolled in this trial over three years.

Conditions

Semilunar Heart Valve Replacement

Outcome Measures

Primary Outcomes (3)

• The ability to perform the new operation in at least 1 patient per year for 3 years (averaged) after enrollment opens.

  This is how feasibility will be measured. This will be answered as "yes" or "no".

  Duration of the study (3 years after enrollment opens).

• Number of participants who achieve survival.

  Safety will primarily be defined as patient survival or re-operation or transcatheter reintervention on the transplanted valve at 6-month intervals, starting 6 months after the first subject undergoes a valve transplant, and continuing until 1 year after all 5 subjected have been enrolled.

  6 months after all 5 subjects have been enrolled.

• Number of participants who achieve survival.

  Safety will primarily be defined as patient survival or re-operation or transcatheter reintervention on the transplanted valve at 6-month intervals, starting 6 months after the first subject undergoes a valve transplant, and continuing until 1 year after all 5 subjected have been enrolled.

  1 year after all 5 subjects have been enrolled.

Secondary Outcomes (3)

• Valve annulus growth.

  Every 6 months following the operation until child is old enough (18+ years) for mechanical prosthesis or date of death, whichever comes first.

• The level of valve stenosis.

  Every 6 months following the operation until child is old enough (18+ years) for mechanical prosthesis or date of death, whichever comes first.

• The level of valve regurgitation.

  Every 6 months following the operation until child is old enough (18+ years) for mechanical prosthesis or date of death, whichever comes first.

Study Arms (1)

Partial Heart Transplantation Arm

EXPERIMENTAL

Procedure: Partial Heart Transplantation

Interventions

Partial Heart Transplantation PROCEDURE

The donor heart will be recovered and the new heart valve will be removed from this heart by the clinical team. The child will be scheduled for an emergent operation once the donor heart valve is deemed acceptable. The child will have general anesthesia during surgery. This is a state of unconsciousness, which is carefully controlled by the anesthesiologist with a mixture of very potent drugs, to prevent or lessen pain. The child will have a partial heart transplant using the donated heart valve to replace the dysfunctional heart valve. Expected hospital stay will range from weeks to months. The medical care after surgery is performed by the child's clinical team. This type of re-operation could similarly be required after a standard heart valve replacement.

Partial Heart Transplantation Arm

Eligibility Criteria

• Age: 1 Day - 2 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Children less than 2 years of age who are referred for a cardiac operation that involves a primary semilunar valve replacement or children less than 2 years of age who are referred for a cardiac operation involves an initial replacement of a previously placed prior homograft, bioprosthetic, or mechanical valve in the aortic or pulmonary position.
• Deemed acceptable for partial heart transplantation based on the standard evaluation process used for orthotopic heart transplantation (see Appendix 1) Insurance approval.
• Written informed consent of both parents/guardians; if there is only one parent/guardian, consent from that individual will be adequate.

You may not qualify if:

• Absolute contraindications for orthotopic heart transplantation.
• Severe bilateral long segment pulmonary arterial hypoplasia
• Bilateral pulmonary vein stenosis
• \<34 weeks corrected gestational age
• Persistent acidosis with a pH \< 7.1
• Diagnosis of immune deficiency.
• Inability for the parent to understand English or Spanish.
• Failure to pass the following psychosocial evaluation:
• The candidate should reside within 4 hours traveling time from Medical University of South Carolina for a minimum of four to six months post-transplantation to assure careful follow-up
• The candidate's family should be capable of long-term supportive care of the child and be able to support the medical needs of the child in follow-up
• Parental (custodial) alcohol and/or substance abuse
• Documented parental (custodial) child abuse or neglect
• Parent (custodian) with cognitive/psychiatric impairment severe enough to limit comprehension of medical regimen
• Evidence of sepsis
• Hepatitis B surface antigenemia

Sponsors & Collaborators

• Medical University of South Carolina: lead

Study Sites (1)

Medical University of South Carolina

Charleston, South Carolina, 29401, United States

Location

Related Publications (1)

• Rajab TK, Ochoa B, Zilinskas K, Kwon J, Taylor CL, Henderson HT, Savage AJ, Kavarana M, Turek JW, Costello JM. Partial heart transplantation for pediatric heart valve dysfunction: A clinical trial protocol. PLoS One. 2023 Feb 7;18(2):e0280163. doi: 10.1371/journal.pone.0280163. eCollection 2023.

  PMID: 36749770 DERIVED

Study Officials

• Taufiek Rajab, MD

  Medical University of South Carolina

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 9, 2022
• First Posted: May 13, 2022
• Study Start: May 3, 2023
• Primary Completion: November 30, 2023
• Study Completion: November 30, 2023
• Last Updated: September 19, 2024

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will share

Locations

US (1)